BioPharma Credit PLC: Lending on Life Sciences under the Microscope
BioPharma Credit PLC (BPCR) is a London-listed investment trust specializing in debt financing for the life sciences sector. Managed by
When the Deal Is the Discovery: Platform Biotechs as Perpetual Option Sellers
Introduction – Deals as the New Discovery
Platform biotech companies today often make headlines not for proven drugs, but for deals
Anatomy of Biopharma Royalty Deals
Biopharma royalty deals are financial transactions where an investor purchases the right to receive future royalty payments from a drug
The Weekly Term Sheet (29)
For large pharmaceutical firms, the week’s deals underscored a willingness to spend on promising science – especially to hedge against
Nvidia, AMD, and the Battle for Biotech AI Hardware in 2025
The biotech industry’s appetite for artificial intelligence has grown insatiable. From AI-driven drug discovery and protein folding to generative
Biotech’s NATO moment: The cock crowed, but will the sun rise?
In June 2025, NATO quietly co‑led a US $35 million Series A funding round for Portal Biotech, a UK
AI in Pharma 2025: Hype, Reality, and the Road Ahead
Artificial intelligence (AI) has permeated the pharmaceutical industry with promises to transform everything from drug discovery to clinical trials. By
Global Clinical Trial Outlook for Late 2025 – Key Readouts and Market Implications
The second half of 2025 is poised to deliver a wave of critical clinical trial readouts across the biopharmaceutical industry.
The Long Quest to Defeat Alzheimer’s – The State of Dementia Research in 2025
Alzheimer’s disease, the most common form of dementia, poses one of the greatest challenges in modern medicine. Every year,
Recursive Evidence and the Fat-Tailed Risk of HTA Circularity
It begins, as all good policies do, with a peer-reviewed article. A study from 2013 estimates the cost of a
